New drug combo offers hope for less aggressive blood cancer

NCT ID NCT02682641

Summary

This study is testing whether a combination of two targeted drugs, ibrutinib and rituximab, can effectively control a slower-growing form of mantle cell lymphoma without using traditional chemotherapy. It is for 50 adults who have been diagnosed but have not yet started any treatment and have minimal or no symptoms. The main goal is to see how many patients achieve a complete remission after one year of this treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, 08036, Spain

  • Hospital Clínico de Valencia

    Valencia, Valencia, Spain

  • Hospital Costa del Sol

    Marbella, Málaga, Spain

  • Hospital General Universitario Santa Lucía

    Cartagena, Murcia, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Clinico de Salamanca

    Salamanca, Spain

  • Hospital Universitario Fundación Alcorcón

    Alcorcón, Madrid, Spain

  • Hospital Universitario Mútua Terrassa

    Terrassa, Barcelona, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, Madrid, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Barcelona, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla, Spain

  • Hospital Universitario de Burgos

    Burgos, Burgos, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Barcelona, Spain

  • Institut Català d'Oncologia

    Barcelona, Barcelona, Spain

  • MD Anderson Cancer Center

    Madrid, Madrid, Spain

Conditions

Explore the condition pages connected to this study.